<p><i>A</i>, A549 cells were treated with LBH589 40 nM and/or a UCN-01 (250 nM) for 24 hours, cell extracts were prepared, and Western blot analysis was performed with PARP (t: total, c: cleaved). Experiments were repeated at least 3 times, and a representative experiment is shown. <i>B</i>, A549 cells were treated with LBH589 and UCN-01 either alone or in combination at a constant ratio (1∶40) for 72 hours. Drug concentrations are indicated on the horizontal axis and plotted against cell viability of control wells, which was arbitrarily set at 100% viability for each experiment. Error bars represent ± SD of 4 replicate wells. <i>C</i>, combined effects of LBH589 and Chk1 inhibitor UCN-01 were quantified with the Chou and Talalay combinatio...
<p>The viability curves of B cells and PBMCs after four days of incubation with different concentrat...
<p>When MK-2206 was combined with the Mek1/2 inhibitor U0126, synergistic cytotoxicity was observed ...
S exposed only to vehicle at various doses of bortezomib, POH, or combination of both for 24 hours. ...
<p>(A) Cell death was measured 48 h post treatment with non-fixed drug ratio combinations of IPI-504...
<p>(A) Cells were treated with HSP70 inhibitor, (VER155008) for 72 h. The relative viability and ICs...
<p>Left hand panels: Growth inhibitory effects of combinations of trametinib with everolimus (TraEvl...
<p><b>A.</b> Clonogenic assays were performed to assess cell survival following BDM and Chk1 inhibit...
<p>(<b>A/B</b>) Killing assays in which target cells and PBMCs were pre-treated for 4 h with (<b>A</...
Chronic myelogenous leukemia (CML) is a cancer described by uncontrolled proliferation of bone marro...
Combinatory drug treatment, e.g. targeting different proteins in specific signaling pathways tailore...
<p>Cell proliferation (A and B) and apoptosis (C and D) assays of HLE (A and C) and SNU-449 (B and D...
<p>(A) Molecular Structure of LBH589. (B) Proliferation and IC<sub>50</sub> analysis of LBH589. Expe...
<p>(A) Structure of Lck inhibitor A-770041. (B) Percent of viable cells of LCL-WT, LCL-FLAG-LMP1 and...
Many anticancer agents damage DNA and arrest cell-cycle progression primarily in S or G2 phase of th...
Purpose: Many tumors exhibit defective cell-cycle checkpoint control and increased replicative stres...
<p>The viability curves of B cells and PBMCs after four days of incubation with different concentrat...
<p>When MK-2206 was combined with the Mek1/2 inhibitor U0126, synergistic cytotoxicity was observed ...
S exposed only to vehicle at various doses of bortezomib, POH, or combination of both for 24 hours. ...
<p>(A) Cell death was measured 48 h post treatment with non-fixed drug ratio combinations of IPI-504...
<p>(A) Cells were treated with HSP70 inhibitor, (VER155008) for 72 h. The relative viability and ICs...
<p>Left hand panels: Growth inhibitory effects of combinations of trametinib with everolimus (TraEvl...
<p><b>A.</b> Clonogenic assays were performed to assess cell survival following BDM and Chk1 inhibit...
<p>(<b>A/B</b>) Killing assays in which target cells and PBMCs were pre-treated for 4 h with (<b>A</...
Chronic myelogenous leukemia (CML) is a cancer described by uncontrolled proliferation of bone marro...
Combinatory drug treatment, e.g. targeting different proteins in specific signaling pathways tailore...
<p>Cell proliferation (A and B) and apoptosis (C and D) assays of HLE (A and C) and SNU-449 (B and D...
<p>(A) Molecular Structure of LBH589. (B) Proliferation and IC<sub>50</sub> analysis of LBH589. Expe...
<p>(A) Structure of Lck inhibitor A-770041. (B) Percent of viable cells of LCL-WT, LCL-FLAG-LMP1 and...
Many anticancer agents damage DNA and arrest cell-cycle progression primarily in S or G2 phase of th...
Purpose: Many tumors exhibit defective cell-cycle checkpoint control and increased replicative stres...
<p>The viability curves of B cells and PBMCs after four days of incubation with different concentrat...
<p>When MK-2206 was combined with the Mek1/2 inhibitor U0126, synergistic cytotoxicity was observed ...
S exposed only to vehicle at various doses of bortezomib, POH, or combination of both for 24 hours. ...